{"generated_at":"2026-08-19T21:03:09.853Z","dossiers":[{"cancer_slug":"melanoma","cancer_name":"Melanoma","kind":"control","disease_id":"MONDO_0005105","visit_count":2,"evidence_visits":2,"last_visit":"2026-08-19T19:27:55.096+00:00","leads":[{"id":"v940-pembrolizumab-kinase-independent-immune-priming","claim":"Intismeran autogene (V940) plus pembrolizumab operationalizes personalized mRNA neoantigen-driven T-cell priming with PD-1 checkpoint blockade in high-risk melanoma, without a kinase-pathway-targeted intervention in the V940 clinical regimen.","level":"lead","title":"V940 plus pembrolizumab: personalized neoantigen immune priming in high-risk melanoma","clamped":"claimed candidate","citations":["NCT05933577","NCT03897881","PMID:42574874","PMID:42481451"],"last_visit":2,"evidence_visits":1,"first_seen_visit":1}],"candidates":[],"dossiers":[],"retired":[],"next_queries":["\"mRNA-4157\" melanoma pembrolizumab neoantigen-specific T cells","\"V940\" melanoma pembrolizumab recurrence-free survival phase 3","\"intismeran autogene\" melanoma biomarkers resistance"]},{"cancer_slug":"nsclc","cancer_name":"NSCLC","kind":"active","disease_id":"MONDO_0005233","visit_count":1,"evidence_visits":1,"last_visit":"2026-08-19T19:28:17.626+00:00","leads":[{"id":"v940-nsclc-phase3","claim":"INTerpath-009 is a recruiting phase 3 NSCLC study of pembrolizumab with or without intismeran autogene (V940); the listed protocol includes platinum-doublet chemotherapy options and has primary completion projected for 2033.","level":"lead","title":"Intismeran autogene (V940) in phase 3 NSCLC","status":"opened","citations":["NCT06623422"],"last_visit":1,"evidence_visits":1,"first_seen_visit":1},{"id":"immunopeptidomics-neoantigen-selection-nsclc","claim":"In 24 NSCLC tumors, HLA-presentation-informed neoantigen selection produced functional responses in 5 of 6 tested patients; 9 of 70 putative neoantigens elicited strong responses.","level":"lead","title":"Immunopeptidomics-guided neoantigen selection","status":"opened","citations":["PMID:42270771"],"last_visit":1,"evidence_visits":1,"first_seen_visit":1},{"id":"antigen-presentation-gating-nsclc-vaccines","claim":"NSCLC immune resistance includes MHC-I, TAP2, B2M, and IFN/JAK-STAT defects, neoantigen loss, and immune-excluded states; these mechanisms constrain neoantigen-vaccine activity.","level":"lead","title":"Antigen-presentation competence as a vaccine-response gate","status":"opened","citations":["PMID:42495623"],"last_visit":1,"evidence_visits":1,"first_seen_visit":1},{"id":"mrna-neoantigen-vaccine-operational-barriers","claim":"Personalized neoantigen mRNA vaccine implementation is constrained by manufacturing timelines, HLA diversity, tumor heterogeneity, and immune editing.","level":"lead","title":"Operational constraints on personalized neoantigen mRNA vaccination","status":"opened","citations":["PMID:41984335"],"last_visit":1,"evidence_visits":1,"first_seen_visit":1}],"candidates":[],"dossiers":[],"retired":[],"next_queries":["\"intismeran autogene\" OR V940 AND non-small cell lung cancer","\"personalized mRNA neoantigen vaccine\" AND NSCLC AND clinical trial","NSCLC neoantigen vaccine immunopeptidomics HLA presentation"]},{"cancer_slug":"bladder","cancer_name":"Bladder","kind":"active","disease_id":"MONDO_0004986","visit_count":0,"evidence_visits":0,"last_visit":null,"leads":[],"candidates":[],"dossiers":[],"retired":[],"next_queries":[]},{"cancer_slug":"pancreatic","cancer_name":"Pancreatic","kind":"active","disease_id":"MONDO_0005192","visit_count":0,"evidence_visits":0,"last_visit":null,"leads":[],"candidates":[],"dossiers":[],"retired":[],"next_queries":[]},{"cancer_slug":"colorectal","cancer_name":"Colorectal","kind":"active","disease_id":"MONDO_0024331","visit_count":0,"evidence_visits":0,"last_visit":null,"leads":[],"candidates":[],"dossiers":[],"retired":[],"next_queries":[]},{"cancer_slug":"renal","cancer_name":"Renal Cell","kind":"active","disease_id":"MONDO_0005086","visit_count":0,"evidence_visits":0,"last_visit":null,"leads":[],"candidates":[],"dossiers":[],"retired":[],"next_queries":[]},{"cancer_slug":"head-neck","cancer_name":"Head & Neck","kind":"active","disease_id":"MONDO_0010150","visit_count":0,"evidence_visits":0,"last_visit":null,"leads":[],"candidates":[],"dossiers":[],"retired":[],"next_queries":[]},{"cancer_slug":"breast","cancer_name":"Breast","kind":"active","disease_id":"MONDO_0004989","visit_count":0,"evidence_visits":0,"last_visit":null,"leads":[],"candidates":[],"dossiers":[],"retired":[],"next_queries":[]},{"cancer_slug":"glioblastoma","cancer_name":"Glioblastoma","kind":"active","disease_id":"MONDO_0018177","visit_count":0,"evidence_visits":0,"last_visit":null,"leads":[],"candidates":[],"dossiers":[],"retired":[],"next_queries":[]},{"cancer_slug":"prostate","cancer_name":"Prostate","kind":"active","disease_id":"MONDO_0005159","visit_count":0,"evidence_visits":0,"last_visit":null,"leads":[],"candidates":[],"dossiers":[],"retired":[],"next_queries":[]},{"cancer_slug":"ovarian","cancer_name":"Ovarian","kind":"active","disease_id":"MONDO_0005140","visit_count":0,"evidence_visits":0,"last_visit":null,"leads":[],"candidates":[],"dossiers":[],"retired":[],"next_queries":[]},{"cancer_slug":"cml","cancer_name":"CML","kind":"control","disease_id":"MONDO_0011996","visit_count":1,"evidence_visits":0,"last_visit":"2026-08-19T19:17:17.836+00:00","leads":[],"candidates":[],"dossiers":[],"retired":[],"next_queries":["\"chronic myeloid leukemia\" personalized mRNA neoantigen vaccine","\"CML\" \"neoantigen vaccine\" mRNA","\"BCR-ABL\" neoantigen mRNA vaccination"]}]}